InsidersTradesSigma
Track the A2M stock price and the full directors' dealings record of the company, a listed equity based in Australia. Shares trade on the AU market, under the supervision of ASX. Market capitalisation: €5.2bn. The latest transaction was reported on 26 August 2026 (Mixed). Among the most active insiders: David Landt Bortolussi. The full history is openly available.
Analysts rate A2M Buy (bullish), based on 10 analysts. Average price target: A$7.70.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
7 of 7 declarations
A2M is a company listed on the XASX, specializing in the development of health products. It focuses on innovation in the healthcare sector.